Codagenix, Inc., a clinical-stage biotechnology startup, has contracted with the Serum Institute of India to manufactuer CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19. Preclinical animal studies have been successfully completed, and the Long Island, New York company expects to initiate a Phase 1 first-in-human clinical trial in...
Codagenix, Inc., a clinical-stage biotechnology startup, has contracted with the Serum Institute of India to manufactuer CDX-005, the company's intranasal, live-attenuated vaccine candidate for SARS-CoV-2, the virus that causes COVID-19. Preclinical animal studies have been successfully completed, and the Long Island, New York company expects to initiate a Phase 1 first-in-human clinical trial in...
